{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:12:43Z","timestamp":1788952363643,"version":"build-2803163510"},"reference-count":44,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Menopause is associated with changes in musculoskeletal, body composition, and metabolic parameters that may be amplified in premenopausal women receiving estradiol suppression for breast cancer. Denosumab offsets deleterious skeletal effects of estradiol suppression and has been reported to have effects on body composition and metabolic parameters in preclinical and observational studies, but evidence from double-blind randomized controlled trials is limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the effect of denosumab on body composition and metabolic parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a prespecified secondary analysis of a 12-month randomized, double-blind, placebo-controlled trial, 68 premenopausal women with breast cancer initiating ovarian function suppression and aromatase inhibition were randomized to denosumab 60-mg or placebo administered at baseline and 6 months. Outcome measures were total and regional fat and lean mass (DXA), body mass index (BMI), waist and hip circumference, fasting glucose, HOMA-IR, and lipid profile. Using a mixed model, between-group mean adjusted differences over time are reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Over 12 months, relative to placebo, android and gynoid fat mass decreased in the denosumab group (\u2212266\u2005g [95% CI \u2212453 to \u221279], P = .02, and \u2212452\u2005g [\u2212783 to \u2212122], P = .03, respectively). Total fat mass and waist circumference were lower in the denosumab group but not significantly (\u22121792 g [\u22123346 to \u2212240], P = .08 and (\u2212 3.77\u2005cm [\u22126.76 to \u22120.79], P = .06, respectively). No significant treatment effects were detected in lean mass, BMI, hip circumference, fasting glucose, HOMA-IR, or lipid profile.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In premenopausal women receiving estradiol suppression, denosumab decreases some measures of fat mass with no detectable effects on other measures of body composition or metabolic parameters.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae003","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T21:11:04Z","timestamp":1704402664000},"page":"e1857-e1866","source":"Crossref","is-referenced-by-count":9,"title":["Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6755-8469","authenticated-orcid":false,"given":"Sabashini K","family":"Ramchand","sequence":"first","affiliation":[{"name":"Department of Medicine, Austin Health, University of Melbourne , Victoria 3084 , Australia"},{"name":"Department of Medicine, Massachusetts General Hospital, Harvard Medical School , MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Hoermann","sequence":"additional","affiliation":[{"name":"Department of Medicine, Austin Health, University of Melbourne , Victoria 3084 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"White","sequence":"additional","affiliation":[{"name":"Department of Medicine, Austin Health, University of Melbourne , Victoria 3084 , Australia"},{"name":"Olivia Newton-John Cancer & Wellness Centre, Austin Health , Victoria 3084 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Yeo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Austin Health, University of Melbourne , Victoria 3084 , Australia"},{"name":"Olivia Newton-John Cancer & Wellness Centre, Austin Health , Victoria 3084 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence A","family":"Francis","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne , Victoria 3052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia L H","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Austin Health, University of Melbourne , Victoria 3084 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D","family":"Zajac","sequence":"additional","affiliation":[{"name":"Department of Medicine, Austin Health, University of Melbourne , Victoria 3084 , Australia"},{"name":"Department of Endocrinology, Austin Health , Victoria 3084 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ego","family":"Seeman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Austin Health, University of Melbourne , Victoria 3084 , Australia"},{"name":"Department of Endocrinology, Austin Health , Victoria 3084 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-3457","authenticated-orcid":false,"given":"Mathis","family":"Grossmann","sequence":"additional","affiliation":[{"name":"Department of Medicine, Austin Health, University of Melbourne , Victoria 3084 , Australia"},{"name":"Department of Endocrinology, Austin Health , Victoria 3084 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"issue":"2","key":"2024091609273731700_dgae003-B1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2024091609273731700_dgae003-B2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2024091609273731700_dgae003-B3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.ijo.0801118","article-title":"Effect of menopausal status on body composition and abdominal fat distribution","volume":"24","author":"Toth","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2024091609273731700_dgae003-B4","first-page":"101781","article-title":"Cardiovascular health and the menopause, metabolic health","author":"Anagnostis","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"2024091609273731700_dgae003-B5","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1210\/clinem\/dgab389","article-title":"Changes in regional fat distribution and anthropometric measures across the menopause transition","volume":"106","author":"Greendale","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024091609273731700_dgae003-B6","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1161\/01.CIR.93.10.1928","article-title":"Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women","volume":"93","author":"Guetta","year":"1996","journal-title":"Circulation"},{"issue":"14","key":"2024091609273731700_dgae003-B7","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-Month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024091609273731700_dgae003-B8","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","article-title":"Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data","volume":"4","author":"Zhu","year":"2019","journal-title":"Lancet Public Health"},{"issue":"7","key":"2024091609273731700_dgae003-B9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis","volume":"1","author":"Muka","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"3","key":"2024091609273731700_dgae003-B10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-017-4282-9","article-title":"Risk of death from cardiovascular disease following breast cancer: a systematic review","volume":"164","author":"Gernaat","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2024091609273731700_dgae003-B11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jnci\/djaa096","article-title":"All-Cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort","volume":"113","author":"Ramin","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2024091609273731700_dgae003-B12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9992","key":"2024091609273731700_dgae003-B13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"30","key":"2024091609273731700_dgae003-B14","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024091609273731700_dgae003-B15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41467-019-14003-6","article-title":"Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism","volume":"11","author":"Weivoda","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"2024091609273731700_dgae003-B16","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1172\/JCI125915","article-title":"RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass","volume":"129","author":"Bonnet","year":"2019","journal-title":"J Clin Invest"},{"issue":"3","key":"2024091609273731700_dgae003-B17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nm.3084","article-title":"Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus","volume":"19","author":"Kiechl","year":"2013","journal-title":"Nat Med"},{"issue":"47","key":"2024091609273731700_dgae003-B18","doi-asserted-by":"crossref","first-page":"e18067","DOI":"10.1097\/MD.0000000000018067","article-title":"Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: effect of denosumab on glycemic parameters","volume":"98","author":"Abe","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2024091609273731700_dgae003-B19","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.metabol.2009.09.019","article-title":"Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women","volume":"59","author":"Nabipour","year":"2010","journal-title":"Metab Clin Exp"},{"key":"2024091609273731700_dgae003-B20","doi-asserted-by":"crossref","first-page":"107992","DOI":"10.1016\/j.diabres.2019.107992","article-title":"Plasma osteoprotegerin as a biomarker of poor glycaemic control that predicts progression of albuminuria in type 2 diabetes mellitus: a 3-year longitudinal cohort study","volume":"161","author":"Moh","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2024091609273731700_dgae003-B21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13052-019-0748-1","article-title":"OPG\/RANK\/RANKL signaling axis in patients with type I diabetes: associations with parathormone and vitamin D","volume":"45","author":"Karalazou","year":"2019","journal-title":"Ital J Pediatr"},{"key":"2024091609273731700_dgae003-B22","doi-asserted-by":"crossref","first-page":"e073435","DOI":"10.1136\/bmj-2022-073435","article-title":"Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study","volume":"381","author":"Lyu","year":"2023","journal-title":"BMJ"},{"issue":"7","key":"2024091609273731700_dgae003-B23","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.2337\/diabetes.53.7.1782","article-title":"Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study","volume":"53","author":"Bonora","year":"2004","journal-title":"Diabetes"},{"issue":"1","key":"2024091609273731700_dgae003-B24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.23736\/S0391-1977.17.02544-5","article-title":"Relationship between insulin resistance, hs-CRP, and body fat and serum osteoprotegerin\/RANKL in prediabetic patients","volume":"43","author":"Bilgir","year":"2018","journal-title":"Minerva Endocrinol"},{"issue":"4","key":"2024091609273731700_dgae003-B25","doi-asserted-by":"crossref","first-page":"e2991","DOI":"10.1002\/dmrr.2991","article-title":"Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial","volume":"34","author":"Napoli","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"2024091609273731700_dgae003-B26","doi-asserted-by":"crossref","first-page":"1809150","DOI":"10.1155\/2020\/1809150","article-title":"Effect of denosumab on glucose homeostasis in postmenopausal women with breast cancer treated with aromatase inhibitors: a pilot study","volume":"2020","author":"Rossini","year":"2020","journal-title":"Int J Endocrinol"},{"key":"2024091609273731700_dgae003-B27","doi-asserted-by":"crossref","first-page":"352858","DOI":"10.1155\/2015\/352858","article-title":"A single 60\u2005mg dose of denosumab might improve hepatic insulin sensitivity in postmenopausal nondiabetic severe osteoporotic women","volume":"2015","author":"Passeri","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"2","key":"2024091609273731700_dgae003-B28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00223-015-0075-5","article-title":"Denosumab inhibition of RANKL and insulin resistance in postmenopausal women with osteoporosis","volume":"98","author":"Lasco","year":"2016","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"2024091609273731700_dgae003-B29","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/jbmr.1865","article-title":"Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials","volume":"28","author":"Schwartz","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024091609273731700_dgae003-B30","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"issue":"1","key":"2024091609273731700_dgae003-B31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/EJE-18-0117","article-title":"Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer","volume":"179","author":"Cheung","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024091609273731700_dgae003-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"key":"2024091609273731700_dgae003-B33","author":"R Core Team"},{"issue":"9","key":"2024091609273731700_dgae003-B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v087.i09","article-title":"Visualizing fit and lack of fit in complex regression models with predictor effect plots and partial residuals","volume":"87","author":"Fox","year":"2018","journal-title":"J Stat Softw"},{"issue":"1","key":"2024091609273731700_dgae003-B35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/03014469700004762","article-title":"Menopause-associated differences in female fat patterning estimated by dual-energy X-ray absorptiometry","volume":"24","author":"Kirchengast","year":"1997","journal-title":"Ann Hum Biol"},{"issue":"5","key":"2024091609273731700_dgae003-B36","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ajcn\/55.5.950","article-title":"Sex- and menopause-associated changes in body-fat distribution","volume":"55","author":"Ley","year":"1992","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"2024091609273731700_dgae003-B37","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1161\/CIRCULATIONAHA.111.067264","article-title":"Body fat distribution and risk of cardiovascular disease: an update","volume":"126","author":"Despres","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"2024091609273731700_dgae003-B38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0021-9150(91)90253-Y","article-title":"Hemorheological disturbances, metabolic parameters and blood pressure in different types of obesity","volume":"88","author":"Wysocki","year":"1991","journal-title":"Atherosclerosis"},{"issue":"11","key":"2024091609273731700_dgae003-B39","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1210\/jc.2008-0804","article-title":"Abdominal and gynoid fat mass are associated with cardiovascular risk factors in men and women","volume":"93","author":"Wiklund","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024091609273731700_dgae003-B40","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/gerona\/glv002","article-title":"Android adiposity and lack of moderate and vigorous physical activity are associated with insulin resistance and diabetes in aging adults","volume":"70","author":"Peterson","year":"2015","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"2024091609273731700_dgae003-B41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/cen.12505","article-title":"Android and gynoid fat percentages and serum lipid levels in United States adults","volume":"82","author":"Min","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2024091609273731700_dgae003-B42","doi-asserted-by":"crossref","first-page":"e27694","DOI":"10.1371\/journal.pone.0027694","article-title":"Android fat depot is more closely associated with metabolic syndrome than abdominal visceral fat in elderly people","volume":"6","author":"Kang","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"2024091609273731700_dgae003-B43","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3349\/ymj.2007.48.5.765","article-title":"Expression and regulation of osteoprotegerin in adipose tissue","volume":"48","author":"An","year":"2007","journal-title":"Yonsei Med J"},{"issue":"2","key":"2024091609273731700_dgae003-B44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13679-023-00505-4","article-title":"Osteoprotegerin\/receptor activator of nuclear factor-kappa B ligand\/receptor activator of nuclear factor-kappa B axis in obesity, type 2 diabetes Mellitus, and nonalcoholic fatty liver disease","volume":"12","author":"Vachliotis","year":"2023","journal-title":"Curr Obes Rep"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae003\/55562380\/dgae003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/10\/e1857\/59135834\/dgae003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/10\/e1857\/59135834\/dgae003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T09:30:43Z","timestamp":1726479043000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/10\/e1857\/7512037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,1,5]]},"published-print":{"date-parts":[[2024,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae003","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,1,5]]}}}